02:04 PM EDT, 04/01/2024 (MT Newswires) -- Solid Biosciences ( SLDB ) said Monday its gene therapy candidate SGT-003 for Duchenne muscular dystrophy has received rare pediatric disease designation from the US Food and Drug Administration.

The designation is designed to encourage development of therapies that target rare pediatric disease and could result in the granting of a priority review voucher if SGT-003 is approved.

SGT-003 also holds the orphan drug and fast track designations in the US.

Solid Biosciences ( SLDB ) shares were down about 6% in recent trading.

Price: 12.55, Change: -0.77, Percent Change: -5.78